Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03015584 · ClinicalTrials.gov registry record
Systems Biology Approach to Cognitive Impairment After SepsiS
A clinical trial, sponsored by Intermountain Health Care.
- Completed
- Registry status
- 40
- Enrollment target
NCT03015584: Completed study, sponsored by Intermountain Health Care.
NCT03015584 is a clinical trial that has completed, run by Intermountain Health Care. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03015584 has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
This study will use systems biology techniques, especially RNA-seq, to understand cognitive impairment after sepsis requiring an intensive care unit (ICU) admission.
Primary Outcome
Measures executive function. 6-month Hayling Sentence Completion test is the prespecified primary outcome.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-07 |
What the finished NCT03015584 record still lists
NCT03015584 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03015584 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03015584 about?
NCT03015584 is a clinical study titled "Systems Biology Approach to Cognitive Impairment After SepsiS". This study will use systems biology techniques, especially RNA-seq, to understand cognitive impairment after sepsis requiring an intensive care unit (ICU) admission.
What is the current status of trial NCT03015584?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2015-06. Estimated completion is 2017-07.
Who is sponsoring clinical trial NCT03015584?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia